A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
- Daniel Reinhorn
- , Michal Sarfaty*
- , Moshe Leshno
- , Assaf Moore
- , Victoria Neiman
- , Eli Rosenbaum
- , Daniel A. Goldstein
*Corresponding author for this work
- Rabin Medical Center Israel
- Tel Aviv University
- University of North Carolina at Chapel Hill
Research output: Contribution to journal › Article › peer-review
32
Scopus
citations